Why GlaxoSmithKline plc, Telecom plus PLC and Kentz Corporation Limited Should Beat The FTSE 100 Today

GlaxoSmithKline plc (LON: GSK), Telecom plus PLC (LON: TEP) and Kentz Corporation Limited (LON: KENZ) move up on a dull day.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The FTSE 100 (FTSEINDICES: ^FTSE) ended yesterday with a 25-point loss, and it’s started today with a further dip of 16 points to 6,682 after ITV shares were downgraded following on from yesterday’s third-quarter update. But the index of top UK shares is only down 11 points on the week so far, and has gained 13% since the start of 2013 — could we be in for a late December surge to push us closer to that record 6,876 level from May?

There’s very little news of individual shares today, but here are three from the various indices that look set to beat the FTSE:

GlaxoSmithKline

Shares in GlaxoSmithKline (LSE: GSK) (NYSE:GSK.US) picked up 9.3p (0.6%) in early trading — not a big rise, but still welcome on a day when the FTSE is falling.

The news today is that the pharmaceuticals giant has completed the sale of part of its stake in Aspen Pharmacare Holdings, having agreed the sale of 28.2 million shares at a price of 250 rand per share. Following the sale, which will net about £425m, Glaxo will sill hold 56.5 million Aspen shares, or 12.4% of the company.

Glaxo shares have been erratic since the Spring, but they’re up around 22% over the past 12 months.

Telecom plus

We need to look outside the FTSE 100 for bigger rises today, and we see Telecom plus shares up a very nice 226p (15%) to 1,733p after the multi-utilities supplier released interim figures and announced an acquisition and share placing.

First-half revenue climbed 17% to £245.8m, with pre-tax profit up 10.1% to £13.7m. Adjusted earnings per share gained 11.5% to 15.5p, and the interim dividend was lifted 23% to 16p per share. These nice figures were made possible by a rise in customer numbers of 33,908, to 494,940.

Telecom Plus has also conditionally agreed to acquire Electricity Plus Supply and Gas Plus Supply from Npower, for a total price of £218m. The deal will be funded by a combination of a new share issue and £100m of borrowing, and will get Telecom plus a 20-year energy-supply deal.

Kentz Corporation

Our third riser for today is Kentz Corporation (LSE: KENZ), whose shares put on 16p (2.9%) to 558p after the company announced a $190m engineering contract with Qatar Petroleum for well-head control systems and corrosion protection for approximately 775 wells in the Dukhan Oilfield in Qatar.

Kentz shares have climbed strongly since the summer, and are now 47% ahead over the past 12 months.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »